What QMENTA does

QMENTA (legal entity Mint Labs, Inc.) is a Boston-headquartered software company, founded in 2013, that operates a cloud-native AI imaging platform purpose-built for regulated clinical trials and neuroimaging research. The platform unifies imaging data ingestion (DICOM, NIfTI, BIDS formats), automated quality control, AI biomarker analysis, and regulatory-grade audit trails into a single governed data layer, with FDA 510(k) clearance and compliance with HIPAA, GDPR, and FDA Title 21 CFR Part 11. Core technical architecture is Docker-container-based and runs on hybrid cloud infrastructure (including Google Cloud Platform), exposing a Python SDK and Jupyter-compatible environment that enables third-party algorithm developers to package and distribute imaging AI tools via a revenue-sharing marketplace.

The company serves four primary customer segments: pharmaceutical sponsors and CROs running imaging endpoints in regulated trials (the primary segment), academic research institutions and imaging core labs, AI algorithm developers seeking a validated clinical deployment channel, and hospitals/healthcare providers. A secondary Legal vertical sells automated DTI quantification (Q-FiberMapper) to law firms and imaging centers on a pay-per-scan basis for TBI litigation. Revenue is generated through enterprise SaaS subscriptions (custom-priced, annual contracts for trials and core labs), usage-based analysis credits (freemium entry with 5 credits), SDK marketplace commissions, and tiered Neuro Data Services subscriptions (Tier 1-4 curated datasets). Named customers include Bayer, Amylyx, Cleveland Clinic, UCSF, NIH, Massachusetts General Hospital, and Alzamend Neuro, with the platform deployed across 250+ imaging sites and processing 16 million images covering 1.3 million subjects.

QMENTA goes to market through a hybrid motion combining direct enterprise field sales (targeting sponsors, CROs, and core labs) with product-led self-serve onboarding (free trial, 5 credits), event-driven demand generation at RSNA and CNS Summit, and developer relations via the SDK and GitHub community. Marketing channels emphasize thought leadership content, scientific case studies, and PR around regulatory milestones. Distribution covers North America (Boston HQ), Europe (Barcelona EU HQ), and an active expansion push into Asia-Pacific via a strategic advisor appointed in 2025. The company operates with 11-50 employees and has raised approximately $10M cumulatively across multiple small rounds since inception, with the most recent disclosed funding of $3.8M led by Flashpoint in July 2020.

Name

QMENTA

Legal name

Mint Labs, Inc.

Website

https://qmenta.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

QMENTA is a Boston-based, FDA 510(k)-cleared cloud platform that provides AI-powered medical imaging analysis, automated quality control, and regulatory-grade data management for pharmaceutical sponsors, CROs, academic research institutions, and AI algorithm developers running clinical trials and neuroimaging research.

Ownership category

akta.pro rank

Product category

Clinical Trial Medical Imaging Software

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

akta.pro secondary industries

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Medical Imaging AI (HDAAAEAH)

Keywords

• Medical imaging platform
• Clinical trial imaging
• Neuroimaging AI
• Imaging biomarkers
• Centralized image review

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. SaaS Platform Subscription: QMENTA operates as a cloud-based SaaS platform where customers pay subscription fees for access to the Imaging Hub, Central Review, and AI biomarker tools. Pricing is subscription-based, typically billed annually, with tiered plans based on usage volume, number of users, and analysis credits. Enterprise contracts cover sponsors, CROs, and core labs on a single platform.
2. Usage-Based Analysis Credits: Customers receive or purchase analysis credits to run AI imaging biomarker tools and workflows on the platform. Each analysis consumes one credit regardless of workflow complexity. Free trial users receive 5 credits. Enterprise contracts define credit allocations and parallel analysis capacity.
3. SDK / Tool Catalog Marketplace: Third-party developers integrate algorithms into QMENTA's tool catalog via the SDK under revenue-sharing agreements. QMENTA markets, distributes, and sells the tools, retaining a share of the revenue. This creates a marketplace commission stream.
4. Neuro Data Services: Curated and annotated neurology imaging datasets sold in tiered levels (Tier 1–4), ranging from aggregated de-identified data to integrated multi-modal datasets with expert radiology assessments and genomic/Real World Data. Over 10 million neurology images have been exchanged or stored on the platform.
5. Pay-per-Scan (Legal Product): The QMENTA Legal product (Q-FiberMapper for TBI litigation) operates on a pay-per-scan model with no commitment required, targeting law firms and imaging centers directly.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

QMENTA provides a cloud-native AI imaging platform for clinical trials and research that governs neuroimaging data from first scan through FDA submission. The platform combines an Imaging Hub (data ingestion, standardization, storage, AI biomarker analysis, and real-time quality control) with a Central Review capability for regulatory-grade endpoint review. QMENTA also operates an SDK-powered tool catalog marketplace for third-party AI algorithms and a curated Neuro Data Services offering across four data tiers.

Product overview

QMENTA is a cloud-native medical imaging platform for clinical trials and research, built as a unified platform-plus-modules architecture. The core QMENTA Platform provides the central infrastructure with the Imaging Hub as the primary interface, which encompasses the Imaging Management System, Smart Uploader, Imaging Cloud storage, and AI Imaging Biomarkers. The platform is offered in three product tiers: Trials (governed neuroimaging for regulated studies), Foundation (AI development and deployment), and Legal (TBI litigation). Key modules include the Central Review Platform for regulatory-grade imaging endpoint review and the SDK for custom algorithm integration. Neuro Data Services provides curated data across four tiers. The platform processes over 16 million images across 250+ sites with FDA 510(k) clearance and zero nonconformities in external pharma audits.

Differentiator

Problem solved

Functional benefit

Brands

• Neuro Data Services: Curated real-world neurology imaging data services with tiered levels of augmented data for AI training, retrospective studies, and biomarker research.
• Q-FiberMapper

Products and services

• QMENTA Platform / Imaging Hub An all-in-one cloud-native imaging platform for clinical trials that provides governed neuroimaging data management, AI analysis, and regulatory-grade evidence production across disease areas, imaging modalities, and trial phases. Sold to pharmaceutical sponsors, CROs, core labs, academic centers, hospitals, and AI firms as the core enterprise offering.
• Central Review Platform Regulatory-grade centralized image review system for imaging endpoints in long-duration oncology and CNS trials, providing longitudinal consistency monitoring, FDA Title 21 CFR Part 11-compliant electronic signatures, audit trails, and access controls. Sold to pharma sponsors, CROs, and core labs.
• Neuro Data Services Curated real-world neurology imaging data service across four tiers: aggregated/tagged clinical data (Tier 1), disease-specific neuroimaging (Tier 2), expert radiology assessments (Tier 3), and integration with genomic/Real World Data (Tier 4). Sold to AI firms, pharma sponsors, and researchers.
• QMENTA Software Development Kit (SDK) Python-based SDK and developer toolkit enabling algorithm developers to package, test, and distribute custom digital biomarker algorithms on the QMENTA platform via Docker containers, with monetization through a revenue-sharing tool catalog marketplace. Targeted at AI imaging biomarker developers.
• Q-FiberMapper (Legal Product) Automated DTI quantification tool for TBI litigation that performs automated segmentation of 33 white matter fiber tracts. Sold on a pay-per-scan basis with no commitment required. Targeted at law firms and imaging centers handling TBI cases.

Quantifiable outcome

• 81% cost reduction vs. on-premise imaging infrastructure ($600K vs. $3.2M) and $1.83M vs. cloud DIY for a 20-site clinical trial scenario
• +6 more outcomes

Named customers10 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability6 records

Feature8 records

Partnerships

Seven partnerships are on record, tiered key advisory, flagship, core, supporting and infrastructure.

• Dr. Montserrat Barcelókey advisoryOthers · 11 March 2026Dr. Montserrat Barceló was appointed as strategic advisor to QMENTA to support global growth and enterprise expansion, with particular focus on Europe and Asia-Pacific markets. Barceló brings healthcare and clinical research leadership experience from TFS HealthScience, Veristat, and other organizations.
• Alzamend NeuroflagshipStrategic or Co-development Partner · 3 June 2025Alzamend Neuro partnered with QMENTA to advance AI-powered imaging for its Phase II clinical trial of AL001 at Massachusetts General Hospital (MGH). QMENTA provides AI-powered imaging analysis for head-to-head studies comparing AL001 versus lithium carbonate products for lithium blood levels and neuroimaging endpoints.
• EIT HealthcoreStrategic or Co-development PartnerQMENTA is partnered with EIT Health, a European initiative supported by the EU that fosters healthcare innovation. QMENTA's logo and partnership are displayed on its website, indicating collaborative alignment on healthcare innovation initiatives. EIT Health is listed as an official partner.
• Curated Neurology Imaging Data PartnerssupportingOthersQMENTA's Neuro Data Services leverages a network of highly qualified partners to provide curated and annotated real-world neurology imaging and clinical data at four tiered levels. These partners provide data aggregation, disease-specific neuroimaging annotation, expert radiology assessments, and genomic/Real World Data integration.
• Google Cloud PlatforminfrastructureTechnology or IntegrationQMENTA's privacy policy identifies Google Cloud Platform as a third-party data processor used both inside and outside the EEA. GCP provides cloud infrastructure and data storage services for the QMENTA platform.
• HubSpotinfrastructureTechnology or IntegrationHubSpot is listed as a third-party data processor in QMENTA's privacy policy. Used for marketing automation, CRM, and website analytics. Data is processed both inside and outside the EEA.
• AtlassianinfrastructureTechnology or IntegrationAtlassian is listed as a third-party data processor in QMENTA's privacy policy, used for internal collaboration and documentation management (e.g., Confluence, Jira).

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Clario: Clario is a clinical trial imaging and endpoint services company offering central reading, image management, and AI-enabled analytics for pharma and CROs. Directly comparable to QMENTA's Trials and Central Review products for the same sponsor and CRO buyer set.
• Medidata (Dassault Systèmes): Medidata's Rave Imaging provides central imaging management, reviewer workflows, and AI biomarker integration within a leading EDC platform. Highly comparable to QMENTA's governed imaging data layer for regulated trials, with a much larger installed base in pharma R&D.
• Median Technologies: Median Technologies provides AI-based imaging biomarkers and central imaging services for oncology clinical trials. Closely comparable to QMENTA's AI Imaging Biomarker catalog and Central Review offerings, particularly for oncology sponsors.
• Calyx (formerly ERT): Calyx delivers clinical trial imaging management, central review, and regulatory submission support to pharma sponsors and CROs. Comparable to QMENTA's Trials and Central Review modules, and competes for the same enterprise imaging RFPs.

Broad incumbents

• IQVIA: IQVIA is the largest global CRO with embedded clinical trial imaging capabilities and a broad services portfolio spanning RWD, EDC, and central labs. Comparable as a broad incumbent that competes for imaging budgets as part of larger outsourcing contracts rather than as a standalone platform.
• Labcorp Drug Development: Labcorp (formerly Covance) provides central lab and clinical trial services including imaging and biomarker workflows for global pharma. Comparable as a large incumbent offering imaging capabilities bundled within broader CRO and lab services.

Emerging players

• Arterys: Arterys offers a cloud-native AI medical imaging platform with FDA-cleared deep learning models across cardiac, lung, and liver workflows. Comparable as an emerging cloud AI imaging peer with overlapping regulatory-grade cloud positioning, though more focused on clinical care than clinical trials.
• Aidoc: Aidoc provides AI-powered medical imaging analysis for clinical workflows in hospitals, with FDA-cleared algorithms for triage and detection. Comparable as an AI imaging peer with overlapping computer-vision capabilities, though primarily serving acute-care radiology rather than trial endpoints.
• Viz.ai: Viz.ai develops AI-driven imaging workflow and care coordination software, initially focused on stroke and expanding across other neuro and cardiovascular indications. Comparable as a regulated AI imaging company leveraging similar DICOM/NIfTI workflows and FDA-cleared models.
• Subtle Medical: Subtle Medical provides AI-based image enhancement and acquisition acceleration for MRI and PET, used in both clinical and research settings. Comparable as an emerging AI imaging peer with overlapping neuro/cardiac use cases and FDA-cleared positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/QMENTA_Inc
• GitHubgithub.com/QMENTA
• LinkedInlinkedin.com/company/qmenta-inc

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds12 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QMENTA